These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 25424771)

  • 41. Anti-HBs seroconversion during treatment with entecavir in a patient with chronic hepatitis B virus infection on hemodialysis.
    Spaziante M; Biliotti E; Grieco S; Palazzo D; Esvan R; Taliani G
    J Med Virol; 2014 Jan; 86(1):139-43. PubMed ID: 24136393
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Diagnosis and treatment of chronic hepatitis B: 2009 update.
    Morgan M; Keeffe EB
    Minerva Gastroenterol Dietol; 2009 Mar; 55(1):5-22. PubMed ID: 19212304
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Chronic hepatitis B virus in young adults: the need for new approaches to management.
    Gill US; Kennedy PT
    Expert Rev Anti Infect Ther; 2014 Sep; 12(9):1045-53. PubMed ID: 25052517
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Four-year Outcomes After Cessation of Tenofovir in Immune-tolerant Chronic Hepatitis B Patients.
    Wong VW; Hui AJ; Wong GL; Chan RS; Chim AM; Lo AO; Chan HL
    J Clin Gastroenterol; 2018 Apr; 52(4):347-352. PubMed ID: 28723855
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Management of chronic hepatitis B patients in immunetolerant phase: what latest guidelines recommend.
    Wong GL
    Clin Mol Hepatol; 2018 Jun; 24(2):108-113. PubMed ID: 29353469
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Characterization of patients with chronic hepatitis B virus infection without indication for treatment].
    Planas R
    Gastroenterol Hepatol; 2014 Jul; 37 Suppl 2():1-4. PubMed ID: 25087704
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Updates in the management of hepatitis B in children.
    Lai MW; Chang MH
    Expert Rev Gastroenterol Hepatol; 2019 Nov; 13(11):1065-1076. PubMed ID: 31663387
    [No Abstract]   [Full Text] [Related]  

  • 48. Unresolved issues of immune tolerance in chronic hepatitis B.
    Lee HW; Chan HL
    J Gastroenterol; 2020 Apr; 55(4):383-389. PubMed ID: 32016713
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Review of Lambda Interferons in Hepatitis B Virus Infection: Outcomes and Therapeutic Strategies.
    Novotny LA; Evans JG; Su L; Guo H; Meissner EG
    Viruses; 2021 Jun; 13(6):. PubMed ID: 34207487
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Current and future directions for treating hepatitis B virus infection.
    Tawada A; Kanda T; Yokosuka O
    World J Hepatol; 2015 Jun; 7(11):1541-52. PubMed ID: 26085913
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The natural history of chronic hepatitis B virus infection.
    Villeneuve JP
    J Clin Virol; 2005 Dec; 34 Suppl 1():S139-42. PubMed ID: 16461215
    [TBL] [Abstract][Full Text] [Related]  

  • 52. New insights in the management of chronic hepatitis B.
    Gill US; Kennedy PT
    Clin Med (Lond); 2015 Apr; 15(2):191-6. PubMed ID: 25824074
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Hepatitis B: Who should be treated?-managing patients with chronic hepatitis B during the immune-tolerant and immunoactive phases.
    Kawanaka M; Nishino K; Kawamoto H; Haruma K
    World J Gastroenterol; 2021 Nov; 27(43):7497-7508. PubMed ID: 34887645
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Fully galactosyl-fucosyl-bisected IgG
    Ho CH; Chen SH; Tsai HW; Wu IC; Chang TT
    Antiviral Res; 2019 Mar; 163():1-10. PubMed ID: 30611775
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Toward Curative Immunomodulation Strategies for Chronic Hepatitis B Virus Infection.
    Zhu W; Liu H; Zhang X
    ACS Infect Dis; 2019 May; 5(5):703-712. PubMed ID: 30907080
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Immune Tolerant Chronic Hepatitis B: The Unrecognized Risks.
    Kennedy PTF; Litwin S; Dolman GE; Bertoletti A; Mason WS
    Viruses; 2017 Apr; 9(5):. PubMed ID: 28468285
    [TBL] [Abstract][Full Text] [Related]  

  • 57. NK cell phenotypic and functional shifts coincide with specific clinical phases in the natural history of chronic HBV infection.
    de Groen RA; Hou J; van Oord GW; Groothuismink ZMA; van der Heide M; de Knegt RJ; Boonstra A
    Antiviral Res; 2017 Apr; 140():18-24. PubMed ID: 28093337
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Liver safety assessment in clinical trials of new agents for chronic hepatitis B.
    Fontana RJ; Avigan MI; Janssen HLA; Regev A; Mishra P; Gaggar A; Brown N; Wat C; Mendez P; Anderson RT; Given B; Miller V; Beumont M
    J Viral Hepat; 2020 Feb; 27(2):96-109. PubMed ID: 31828894
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Definition and Management of the Immune Tolerance Phase in Chronic Hepatitis B].
    Hong YM; Yoon KT
    Korean J Gastroenterol; 2022 Apr; 79(4):156-160. PubMed ID: 35473773
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Should Treatment Indications for Chronic Hepatitis B Be Expanded?
    Jeng WJ; Lok AS
    Clin Gastroenterol Hepatol; 2021 Oct; 19(10):2006-2014. PubMed ID: 32434068
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.